Our laboratory focuses on Multiple Myeloma (MM), a cancer of plasma cells (mature antibody-producing lymphocytes). Myeloma is the second most common hematological malignancy. In thelast decade, a small molecular lproteasome inhibitor called bortezomib has become a primary contender in MM treatment. Inevitably, the maignancy gains drug resistance to bortezomib, expands throughout the bone marrow, and ultimately klls the patient. My research will analyze and evaluate both the cell autonomus and non-cell autonomous routes of acquired drug resistance in MM, together with collaborators.